# Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis

Study · id `cardio:ct-nct02722447` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02722447](<https://clinicaltrials.gov/study/NCT02722447>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02722447

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1100 participants.

## Technical summary

Registry record NCT02722447. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2019-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1100 participants (planned count; ClinicalTrials.gov record NCT02722447, source copy `cardio:ctgov-nct02722447-2018-11-27`, retrieved 2026-10-31)
- Started: 2017-01 (actual) (ClinicalTrials.gov record NCT02722447, source copy `cardio:ctgov-nct02722447-2018-11-27`, retrieved 2026-10-31)
- Primary completion: 2019-06 (anticipated) (ClinicalTrials.gov record NCT02722447, source copy `cardio:ctgov-nct02722447-2018-11-27`, retrieved 2026-10-31)
- Completion: 2021-06 (anticipated) (ClinicalTrials.gov record NCT02722447, source copy `cardio:ctgov-nct02722447-2018-11-27`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT02722447, source copy `cardio:ctgov-nct02722447-2018-11-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02722447-2018-11-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
- Acronym: RIDTS
- Condition: Deep Vein Thrombosis
- Intervention (Drug): rivaroxaban
- Intervention (Drug): Placebo
- Lead sponsor: Walter Ageno
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial (`cardio:pubmed-36520715`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6cc0f42c95be21a27377b9ee51a5e2ee1bfec1870e804d3ebe483217d31bd9a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
